Frequently Asked Questions
Answers about consultations, peptide therapy, GLP-1 programs, pricing, and regulatory considerations.
Consulting & Process
No. All therapies require evaluation by a licensed medical provider. Prescriptions are issued only when clinically appropriate.
You will:
- Complete a structured medical intake
- Meet virtually with a licensed provider
- Discuss your medical history and goals
- Review therapy options and regulatory considerations
If therapy is appropriate, your prescription may be issued following evaluation.
The consultation fee covers provider evaluation time and is non-refundable once the appointment occurs.
Appointment availability varies by state and provider schedule. Most patients can book within a few days.
Pricing
If peptide therapy is approved, the $300 total includes:
- Your $99 consultation
- One peptide therapy for the first month
This is not a subscription and does not automatically renew.
Additional peptides may be added after the first month when clinically indicated. Additional therapies are typically $250 each.
GLP-1 programs range from $275–$475 depending on prescribed therapy.
Final pricing is discussed during consultation.
No. There are no forced long-term contracts or automatic subscription traps.
Peptide therapy
Many compounded peptide therapies are not FDA-approved for specific indications.
Compounded medications are not approved for the diagnosis, treatment, cure, or prevention of disease.
Your provider will discuss regulatory status during consultation.
Safety depends on individual health history and proper medical oversight.
All therapies require physician evaluation and monitoring.
Treatment decisions are made by licensed medical providers based on clinical evaluation.
You may discuss goals during consultation, but prescribing decisions are not guaranteed.
Additional peptides are typically considered after the first month when clinically appropriate.
GLP-1 programs
Providers may evaluate patients for:
- Semaglutide-based programs
- Tirzepatide-based programs
Therapy is prescribed only when clinically appropriate.
Compounded medications are not FDA-approved and may not undergo the same review process as FDA-approved medications.
Insurance coverage varies and is discussed during consultation.
Pharmacy & Legal
Prescriptions are transmitted to licensed 503A or 503B compounding pharmacies when appropriate.
Bridgeside does not manufacture or dispense medications directly.
Peptide telehealth is legal when prescribed by a licensed provider and fulfilled by a licensed pharmacy in compliance with state and federal regulations.
Availability varies by state.
Information on this website is for educational purposes only and does not constitute medical advice.
Individual results vary.
General
Many patients are seeking peptide telehealth:
- Are physically active
- Focus on recovery and performance
- Prefer physician-guided oversight
- Want structured and compliant access
Eligibility is determined only after evaluation.